Lipocine completes last patient last visit in Phase 3 trial of LPCN 1154 for PPD

Lipocine Inc.

Last patient completed final visit in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression.
Trial enrolled 90 patients with severe PPD (average baseline HAM-D 28.3); positive safety profile with no discontinuations.
Company expects Phase 3 data to support 505(b)(2) NDA submission for LPCN 1154 in 2026.
Preliminary cash and equivalents ~$19M as of Jan 31, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.